P0897 Serum concentrations of infliximab are comparable with and without immunosuppression during subcutaneous infliximab induction treatment for Crohn’s disease
S Anjie(Amsterdam University Medical Centers), K B Gecse(Amsterdam University Medical Centers), Lotte Oldenburg(Amsterdam Neuroscience), Bindia Jharap(Meander Medisch Centrum), Marjolijn Duijvestein(Amsterdam University Medical Centers), Inge C. Boukema(Amsterdam University Medical Centers), Esmé Clasquin(Amsterdam University Medical Centers), T. Römkens(Jeroen Bosch Ziekenhuis), D I Park(Kangbuk Samsung Hospital), B D Ye(Asan Medical Center), J Maljaars(Leiden University Medical Center), I Van Welsen(Amsterdam University Medical Centers), G D’Haens(Amsterdam UMC Location University of Amsterdam), S B Kang(St. Mary's Hospital), T O Kim(Inje University Haeundae Paik Hospital), J M Jansen(OLVG), E S Kim(Kyungpook National University), J Van Oostrom(Amsterdam University Medical Centers), Bas Oldenburg(University Medical Center Utrecht), W Mares(Ziekenhuis Gelderse Vallei), Roel Janssen(Amsterdam University Medical Centers)
Cited by 0
Related Papers
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
|Clinical and Translational Gastroenterology|2016|724
Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial
|The Lancet Oncology|2011|470
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252